Orphalan was incorporated in 2011 to reposition drugs in orphan diseases by exploiting untapped academic research and existing clinical data. The lead indication is Wilson’s disease which results from the toxic accumulation of copper in the body. Current treatments are not satisfactory due to harmful side effects or complex drug handling requirements. Orphalan has developed a best in class molecule to address this unmet medical need.
Employees: 11-50